The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. Accordingly, the present invention provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.
本发明揭示了高度同工酶选择性的蛋白激酶C beta-1和beta-2同工酶
抑制剂化合物。因此,本发明提供了一种选择性地抑制蛋白激酶C同工酶beta-1和beta-2的方法。作为beta-1和beta-2同工酶选择性
抑制剂,这些化合物在治疗与糖尿病及其并发症相关的疾病状态以及与beta-1和beta-2同工酶升高相关的其他疾病状态方面具有治疗用途。